SAREPTA THERAPEUTICS, INC. Payments to Acquire Marketable Securities
SAREPTA THERAPEUTICS, INC. (SRPT) reported Payments to Acquire Marketable Securities of $112.99 million for the 401-month period ending 2013-12-31, per its 10-K filed 2014-03-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2014-03-03
- SAREPTA THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2012-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2012-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2012-06-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2012-03-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2012 was $0.00.
- SAREPTA THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2011 was $0.00, a 100.00% decline from fiscal 2010.
- SAREPTA THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2010 was $7.00K.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 371 month | Payments to Acquire Marketable Securities 374 month | Payments to Acquire Marketable Securities 377 month | Payments to Acquire Marketable Securities 380 month | Payments to Acquire Marketable Securities 383 month | Payments to Acquire Marketable Securities 386 month | Payments to Acquire Marketable Securities 389 month | Payments to Acquire Marketable Securities 392 month | Payments to Acquire Marketable Securities 395 month | Payments to Acquire Marketable Securities 398 month | Payments to Acquire Marketable Securities 401 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013-12-31 | $112.99M 10-K · filed 2014-03-03 | ||||||||||||||
| 2013-09-30 | $112.99M 10-Q · filed 2013-11-12 | ||||||||||||||
| 2013-06-30 | $112.99M 10-Q · filed 2013-08-08 | ||||||||||||||
| 2013-03-31 | $112.99M 10-Q · filed 2013-05-09 | ||||||||||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 10-K · filed 2013-03-15 | $112.99M 10-K · filed 2013-03-15 | ||||||||||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | $0.00 derived: sum of 4 quarters · filed 2013-03-15 | $112.99M 10-Q · filed 2012-11-07 | ||||||||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $0.00 10-Q · filed 2012-08-07 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 derived: sum of 4 quarters · filed 2013-03-15 | $112.99M 10-Q · filed 2012-08-07 | ||||||||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-10 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 derived: sum of 4 quarters · filed 2013-03-15 | $112.99M 10-Q · filed 2012-05-10 | ||||||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 10-K · filed 2013-03-15 | $112.99M 10-K · filed 2012-03-13 | ||||||||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | $2.00K derived: sum of 4 quarters · filed 2013-03-15 | $112.99M 10-Q · filed 2011-11-08 | ||||||||||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $0.00 10-Q · filed 2012-08-07 | $2.00K derived: sum of 3 quarters · filed 2013-03-15 | $112.99M 10-Q · filed 2011-08-08 | |||||||||||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-10 | $2.00K derived: sum of 2 quarters · filed 2013-03-15 | |||||||||||||
| 2010-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $7.00K 10-K · filed 2013-03-15 | |||||||||||||
| 2010-09-30 | $5.00K 10-Q · filed 2011-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |